nsc 664704 has been researched along with Amyotrophic Lateral Sclerosis in 1 studies
kenpaullone: inhibits CDK1/cyclin B; structure in first source
kenpaullone : An indolobenzazepine that is paullone in which the hydrogen at position 9 is replaced by a bromo substituent. It is an ATP-competitive inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3beta (GSK3beta).
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, YM | 1 |
| Gupta, SK | 1 |
| Kim, KJ | 1 |
| Powers, BE | 1 |
| Cerqueira, A | 1 |
| Wainger, BJ | 1 |
| Ngo, HD | 1 |
| Rosowski, KA | 1 |
| Schein, PA | 1 |
| Ackeifi, CA | 1 |
| Arvanites, AC | 1 |
| Davidow, LS | 1 |
| Woolf, CJ | 1 |
| Rubin, LL | 1 |
1 other study available for nsc 664704 and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Benzazepines; Cell Differentiation; Cell Survival; Cells, Cu | 2013 |